364 related articles for article (PubMed ID: 33118682)
1. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen.
Gómez-García de la Banda M; Amaddeo A; Khirani S; Pruvost S; Barnerias C; Dabaj I; Bénézit A; Durigneux J; Carlier RY; Desguerre I; Quijano-Roy S; Fauroux B
Pediatr Pulmonol; 2021 Jan; 56(1):299-306. PubMed ID: 33118682
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
3. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.
LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
Am J Respir Crit Care Med; 2019 Dec; 200(12):1547-1550. PubMed ID: 31433957
[No Abstract] [Full Text] [Related]
4. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
5. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
[TBL] [Abstract][Full Text] [Related]
6. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.
Aragon-Gawinska K; Daron A; Ulinici A; Vanden Brande L; Seferian A; Gidaro T; Scoto M; Deconinck N; Servais L;
Dev Med Child Neurol; 2020 Mar; 62(3):310-314. PubMed ID: 31799720
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
[TBL] [Abstract][Full Text] [Related]
8. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.
Chacko A; Sly PD; Ware RS; Begum N; Deegan S; Thomas N; Gauld LM
Thorax; 2022 Jan; 77(1):40-46. PubMed ID: 33963091
[TBL] [Abstract][Full Text] [Related]
9. [Spinal muscular atrophy treated with nusinersen].
Boesen MS; Albrechtsen S; Born AP
Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
[TBL] [Abstract][Full Text] [Related]
10. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
[TBL] [Abstract][Full Text] [Related]
11. Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function.
Serrão C; Domingues S; de Campos CF; Moreira S; Conceição I; de Carvalho M; Oliveira Santos M
Neurol Sci; 2024 Jun; 45(6):2887-2891. PubMed ID: 38589769
[TBL] [Abstract][Full Text] [Related]
12. Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function.
Pane M; Palermo C; Messina S; Sansone VA; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Brigati G; de Sanctis R; Coratti G; Lucibello S; Bertini E; Vita G; Tiziano FD; Mercuri E;
Neuromuscul Disord; 2018 Jul; 28(7):582-585. PubMed ID: 29960818
[TBL] [Abstract][Full Text] [Related]
13. Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
Le Goff L; Seferian A; Phelep A; Rippert P; Mathieu ML; Cances C; de Lattre C; Durigneux J; Gousse G; Vincent-Genod D; Ribault S; Gomez Garcia de la Banda M; Quijano-Roy S; Sarret C; Servais L; Vuillerot C
Neurol Sci; 2023 Jan; 44(1):329-337. PubMed ID: 36175810
[TBL] [Abstract][Full Text] [Related]
14. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression.
Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS
J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614
[TBL] [Abstract][Full Text] [Related]
16. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen.
Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C
Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659
[TBL] [Abstract][Full Text] [Related]
17. Effect of Salbutamol on Respiratory Muscle Strength in Spinal Muscular Atrophy.
Khirani S; Dabaj I; Amaddeo A; Olmo Arroyo J; Ropers J; Tirolien S; Coudert V; Estournet B; Fauroux B; Quijano-Roy S
Pediatr Neurol; 2017 Aug; 73():78-87.e1. PubMed ID: 28668232
[TBL] [Abstract][Full Text] [Related]
18. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
[TBL] [Abstract][Full Text] [Related]
19. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
20. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
